Larimar Therapeutics, Inc. (LRMR)
3.83
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
3.85
+0.02
(+0.52%)
After-Hours: 20:00
Larimar Therapeutics Cash from Operations (Quarterly) : -44.03M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -44.03M |
| March 31, 2026 | -44.61M |
| December 31, 2025 | -38.53M |
| September 30, 2025 | -28.75M |
| June 30, 2025 | -19.38M |
| March 31, 2025 | -26.54M |
| December 31, 2024 | -21.82M |
| September 30, 2024 | -24.55M |
| June 30, 2024 | -13.99M |
| March 31, 2024 | -10.41M |
| December 31, 2023 | -9.343M |
| September 30, 2023 | -9.20M |
| June 30, 2023 | -7.365M |
| March 31, 2023 | -7.551M |
| December 31, 2022 | -6.672M |
| September 30, 2022 | -5.878M |
| June 30, 2022 | -7.486M |
| March 31, 2022 | -7.533M |
| December 31, 2021 | -7.918M |
| September 30, 2021 | -12.20M |
| June 30, 2021 | -10.78M |
| March 31, 2021 | -11.21M |
| December 31, 2020 | -9.856M |
| September 30, 2020 | -11.23M |
| June 30, 2020 | -12.20M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.921M |
| December 31, 2019 | -7.911M |
| September 30, 2019 | -5.823M |
| June 30, 2019 | 3.506M |
| March 31, 2019 | -12.47M |
| December 31, 2018 | -11.83M |
| September 30, 2018 | -13.08M |
| June 30, 2018 | -13.31M |
| March 31, 2018 | -13.26M |
| December 31, 2017 | -9.836M |
| September 30, 2017 | -12.09M |
| June 30, 2017 | -10.18M |
| March 31, 2017 | -11.68M |
| December 31, 2016 | -8.666M |
| September 30, 2016 | -11.03M |
| June 30, 2016 | -14.52M |
| March 31, 2016 | -17.76M |
| December 31, 2015 | -17.94M |
| September 30, 2015 | -16.14M |
| June 30, 2015 | -14.39M |
| March 31, 2015 | -11.09M |
| December 31, 2014 | -11.71M |
| September 30, 2014 | -6.278M |
| June 30, 2014 | -6.229M |
| March 31, 2014 | -4.02M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | -7.588M |
| Marker Therapeutics, Inc. | -3.716M |
| Rezolute, Inc. | -13.74M |
| Krystal Biotech, Inc. | 74.79M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -40.91M |
| Cash from Financing (Quarterly) | -0.435M |
| Free Cash Flow | -156.08M |
| Free Cash Flow Per Share (Quarterly) | -0.4231 |
| Free Cash Flow to Equity (Quarterly) | -45.34M |
| Free Cash Flow to Firm (Quarterly) | -44.16M |
| Free Cash Flow Yield | -45.48% |